mRNA Therapeutics Contract Development & Manufacturing Organization Market Size | key Companies
The mRNA therapeutics contract development & manufacturing organization market size was exhibited at USD 4.85 billion in 2024 and is projected to hit around USD 14.14 billion by 2034, growing at a CAGR of 11.29% during the forecast period 2025 to 2034.
The U.S. mRNA therapeutics contract development & manufacturing organization market size reached USD 1.4 billion in 2024 and is anticipated to be worth around USD 4.0 billion by 2034, poised to grow at a CAGR of 10.01% from 2025 to 2034.
The North America mRNA therapeutics contract development & manufacturing organization market accounted for the largest share of 38.00% of the global revenue in 2024. The market growth is driven by established CDMOs, increasing clinical trials, and a growing prevalence of infectious diseases, respiratory diseases, and cardiovascular & cerebrovascular diseases in North America. For instance, in February 2024, Arcturus Therapeutics and CSL announced the results of a follow-up on the ARCT-154 booster dose Phase 3 study. It was the first sa-mRNA COVID-19 vaccine approved globally and can be administered at one-sixth the dose of Comirnaty (5 μg vs 30 μg).
U.S. mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends
The mRNA therapeutics contract development & manufacturing organization market in the U.S. held the largest share in 2024. The country accounts for the highest share of the North America regional market, as many pharmaceutical and life sciences companies are present in this country. Growing interest in clinical trials and the benefits of live biotherapeutics in treating rare diseases drive the development of new & novel drugs. Moreover, a well-established regulatory framework provides new opportunities for companies to develop and manufacture products with wide applications & target populations and improved knowledge of the importance of mRNA in terms of therapeutics.
Europe mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends
The Europe mRNA therapeutics contract development & manufacturing organization market is expected to grow significantly. Due to the COVID-19 pandemic, vaccine developers entered into strategic agreements with contract development and manufacturing service providers to meet the urgent global demand for mRNA-based vaccines, which led to significant growth in the outsourcing industry. Moreover, manufacturing mRNA therapeutics is complex, cost-intensive, and requires skilled professionals. Thus, several small- to medium-sized companies rely on CDMO to produce mRNA-synthesized products to innovate new mRNA therapeutics.
The mRNA therapeutics contract development & manufacturing organization market in Germany held the largest share in 2024 owing to a substantial number of providers offering mRNA therapeutics and initiatives undertaken to expand the scope of these tools. For instance, in February 2024, BioNTech announced that it would invest USD 43 million to establish an mRNA manufacturing facility in Germany. Therefore, the market is expected to be driven by rising investments in mRNA technology.
The UK mRNA therapeutics contract development & manufacturing organization market is anticipated to grow over the forecast period. Increasing government initiatives to support mRNA therapeutics development and accelerate clinical trials for mRNA immune therapies drive market growth. For instance, in January 2024, BioNTech announced a strategic collaboration with the UK government to deliver personalized mRNA cancer immunotherapies to around 10,000 patients by 2030. This multiyear partnership focuses on three key strategic pillars: cancer immunotherapies, vaccines for infectious diseases, and expanding BioNTech's presence in the UK.
Asia Pacific mRNA Therapeutics Contract Development & Manufacturing Organization Market Trends
The mRNA therapeutics contract development & manufacturing organization market in Asia Pacific is expected to grow at a CAGR of 10.83% from 2024 to 2034. Key factors contributing to this growth are increasing R&D investments, the rising prevalence of diseases that can be targeted by mRNA therapies, and advancements in technology.
The China mRNA therapeutics contract development & manufacturing organization market is expected to grow over the forecast period. Significant investments in expanding and upgrading manufacturing infrastructure for mRNA therapies in China are expected to drive market growth in the near future.
The mRNA therapeutics contract development & manufacturing organization market in Japan held the largest share in 2024 due to growing initiatives to set up drug discovery infrastructure in Japan, rising investments by private & public sectors, and strategic initiatives, such as mergers & acquisitions, by key companies. For instance, in August 2022, Ricoh Company Ltd. announced the establishment of a Ricoh Biomedical Startup Fund to support mRNA drug R&D in Japan.
The India mRNA therapeutics contract development & manufacturing organization market is anticipated to grow at the fastest CAGR over the forecast period. This growth can be attributed to the availability of a large pool of skilled scientists, researchers, and professionals in biotechnology & pharmaceuticals.
| Report Coverage | Details |
| Market Size in 2025 | USD 5.40 Billion |
| Market Size by 2034 | USD 14.14 Billion |
| Growth Rate From 2025 to 2034 | CAGR of 11.29% |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Segments Covered | Application, Indication, End-use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional scope | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | Danaher (Aldevron); Biomay AG; Bio-Synthesis, Inc.; eTheRNA; Kaneka Eurogentec S.A.; TriLink BioTechnologies; ApexBio Technology; BioNTech SE; BioCina; Lonza; Recipharm AB; Novo Holdings (Catalent, Inc.); Samsung Biologics |
On the basis of application segment, the market is segregated into viral vaccines, protein replacement therapies, and cancer immunotherapies. The viral vaccines segment led the market, accounting for 100% of global revenue in 2024. The demand in the segment can be attributed to established technology, the wide applicability of viral vaccines, and the launch of various mRNA-based vaccines to control the spread of the COVID-19 virus. For instance, in January 2024, Moderna announced mRNA-1345, an investigational respiratory syncytial virus vaccine. Phase 3 trial involves studying the coadministration of flu vaccine and COVID-19 (mRNA-1083) for older adults and is fully enrolled.
This phase 3 study data is expected in 2024. Furthermore, expanding the mRNA vaccine pipeline is expected to drive market growth in the coming decade. The development of mRNA vaccines to treat various infectious diseases is also increasing. Companies have begun including vaccinations for various diseases, such as influenza, Zika, and Cytomegalovirus (CMV), in their pipelines along with COVID-19. This trend indicates the versatility of mRNA vaccines. Such factors are anticipated to drive market growth. The cancer immunotherapies segment is anticipated to grow at the fastest CAGR over the forecast period.
The growth is attributed to the increasing cancer prevalence and investments to develop novel therapies to combat this growing prevalence. Cancer immunotherapies, including mRNA-based approaches, are showing significant promise and attracting considerable attention in oncology. mRNA cancer vaccines represent a potent and adaptable approach to immunotherapy. The primary advantage of mRNA cancer immunotherapies is their potent immunogenicity, which triggers strong cell-mediated and humoral immune responses, thus contributing to market growth.
On the basis of indication segment, the market is segregated into infectious diseases, metabolic & genetic diseases, and cardiovascular & cerebrovascular diseases. The infectious diseases segment dominated the market in 2024, accounting for a revenue share of 100.00%. The increasing adoption of mRNA-based vaccines, a high number of candidates entering clinical trials for various infectious diseases, and the COVID-19 outbreak in late 2019 have led to the dominance of this segment. Moreover, the prevalence of infectious diseases has long been a global health problem, and mRNA therapies have emerged as promising tools in combating these diseases.
mRNA therapeutics promises growth regarding infectious diseases, and the market represents a dynamic & fast-growing segment with unique advantages and growth potential. The growing incidence of respiratory diseases has highlighted the need for rapid and flexible vaccine development. For instance, in February 2024, ReCode Therapeutics mentioned that the first volunteer had been dosed in a Phase 1 clinical study of RCT2100. It is an inhaled investigational therapy based on mRNA for cystic fibrosis that is focused on 10-13% of patients with nonsense mutations who do not experience any side effects with approved CFTR modulators.
The metabolic & genetic segment is anticipated to grow at a rapid CAGR of 11.65% over the forecast period. This segment includes cancer and other genetic diseases. The segment growth is attributed to the subsequent number of products under development for these applications. For instance, in February 2024, Moderna entered into an agreement with Life Edit Therapeutics to address genetic diseases using mRNA-based gene editing. This partnership combines Moderna’s mRNA platform with Life Edit’s specialized gene editing capabilities, including an emerging and precise gene editing technique called base editing.
On the basis of the end-uses, the market is segregated into biotech companies, pharmaceutical companies, and government & academic research institutes. The biotech companies segment dominated the market share of 65.0% in 2024. due to the growing need for therapeutics for COVID-19 and increasing trend of outsourcing end-to-end services, especially among small- and mid-sized biotechnology companies that lack expertise in mRNA development. Moreover, strategic initiatives, such as partnerships and collaborations, with CDMO have helped biotech companies to generate profitable revenues. For instance, in September 2024, PackGene Biotech Inc. and Kudo Biotechnology formed a strategic partnership to offer high-quality mRNA manufacturing services for drug and vaccine development.
This collaboration encompasses comprehensive support for mRNA development, gene-to-mRNA conversion, Lipid Nanoparticle (LNP) formulation development, encapsulation, and production of finished drug products. The government & research institutes segment is expected to grow at the fastest CAGR of 11.55% from 2025 to 2034. The segment growth is due to rising investment by government bodies to develop novel therapies for chronic diseases and an elevated interest in healthcare post the major challenges faced due to the pandemic. For instance, in March 2024, the U.S. government invested USD 31.9 billion in research and procurement of mRNA vaccines. The investment will support the development, production & purchasing of mRNA-based COVID-19 vaccines through the National Institutes of Health to the Department of Defense. It aimed to enhance overall support for mRNA COVID-19 vaccine production.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the mRNA therapeutics contract development & manufacturing organization market
By Application
By Indication
By End-use
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers